Nancy L Levin

US Patent:

20060205660, Sep 14, 2006

Filed:

May 11, 2006

Appl. No.:

11/433186

Inventors:

Frederic Sauvage - Foster City CA, US
Nancy Levin - Newbury Park CA, US
Richard Vandlen - Hillsborough CA, US

International Classification:

A61K 38/17
C07K 14/705
C07H 21/04
C12P 21/06

US Classification:

514012000, 435069100, 435320100, 435325000, 530350000, 536023500

Abstract:

The present invention concerns long-half derivative of the obesity protein OB. The invention specifically concerns OB protein-immunoglobulin chimeras and polyethylene glycol (PEG)-OB derivatives, which have extended half-life as compared to the corresponding native OB proteins. The invention further relates to methods for appetite and/or weight reducion and for treating other physiological conditions by using the long half-life derivatives of OB.

US Patent:

6620413, Sep 16, 2003

Filed:

Dec 27, 1996

Appl. No.:

08/775066

Inventors:

Frederic DeSauvage - Foster City CA
Nancy Levin - Newbury Park CA
Richard Vandlen - Hillsborough CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39395

US Classification:

4241781, 4241791, 514 2, 530350

Abstract:

The present invention concerns long-half derivative of the obesity protein OB. The invention specifically concerns OB protein-immunoglobulin chimeras and polyethylene glycol (PEG)-OB derivatives, which have extended half-life as compared to the corresponding native OB proteins. The invention further relates to methods for treating obesity by using the long half-life derivatives of OB.

US Patent:

20200085789, Mar 19, 2020

Filed:

Mar 7, 2018

Appl. No.:

16/493155

Inventors:

- Couvet, CH
Nancy LEVIN - La Jolla CA, US
Benjamin WINOGRAD - West Orange NJ, US

International Classification:

A61K 31/407
A61K 31/4015
A61N 5/10
A61P 25/00
A61P 35/00
C07K 16/22
A61N 1/36

Abstract:

The present disclosure is related to dosage strategies for the treatment of CNS cancers with proteasome inhibitors (e.g., marizomib). For instance, the disclosure is related to strategies in which a proteasome inhibitor (e.g., marizomib) is administered at the same or higher dosage even after a subject has experienced a CNS-related adverse event.

US Patent:

20180106810, Apr 19, 2018

Filed:

Sep 6, 2017

Appl. No.:

15/696684

Inventors:

Michael Tainsky - Southfield MI, US
Madhumita Chatterjee - Lake Orion MI, US
Gregory Dyson - Northville MI, US
Nancy Levin - Birmingham MI, US

Assignee:

Wayne State University - Detroit MI

International Classification:

G01N 33/574
C07K 16/32
G01N 33/564

Abstract:

Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.

US Patent:

20180031565, Feb 1, 2018

Filed:

Oct 17, 2017

Appl. No.:

15/785898

Inventors:

Michael Tainsky - Southfield MI, US
Madhumita Chatterjee - Lake Orion MI, US
Gregory Dyson - Northville MI, US
Nancy Levin - Birmingham MI, US

Assignee:

Wayne State University - Detroit MI

International Classification:

G01N 33/574
C07K 14/47

Abstract:

Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.

US Patent:

20170348284, Dec 7, 2017

Filed:

Jun 1, 2017

Appl. No.:

15/611614

Inventors:

- Pembroke, BM
Ann MacLaren - La Jolla CA, US
Nancy Levin - La Jolla CA, US

International Classification:

A61K 31/407
A61K 31/495
A61K 39/395
A61N 5/10
A61K 39/00

Abstract:

The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.

US Patent:

20150139980, May 21, 2015

Filed:

May 6, 2013

Appl. No.:

14/398773

Inventors:

Michael Tainsky - Southfield MI, US
Madhumita Chatterjee - Lake Orion MI, US
Gregory Dyson - Northville MI, US
Nancy Levin - Birmingham MI, US

International Classification:

G01N 33/574
G01N 33/564
C07K 16/32

US Classification:

4241331, 506 18, 436501, 435 792, 506 9, 5303879, 435 74

Abstract:

Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.